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Elise A. KikisAbstract
The presence of only small amounts of misfolded protein is an indication of a healthy proteome. Maintaining
proteome health, or more specifically, “proteostasis,” is the purview of the “proteostasis network.” This network must
respond to constant fluctuations in the amount of destabilized proteins caused by errors in protein synthesis and
exposure to acute proteotoxic conditions. Aging is associated with a gradual increase in damaged and misfolded
protein, which places additional stress on the machinery of the proteostasis network. In fact, despite the ability of
the proteostasis machinery to readjust its stoichiometry in an attempt to maintain homeostasis, the capacity of cells
to buffer against misfolding is strikingly limited. Therefore, subtle changes in the folding environment that occur
during aging can significantly impact the health of the proteome. This decline and eventual collapse in proteostasis
is most pronounced in individuals with neurodegenerative disorders such as Alzheimer’s Disease, Parkinson’s
Disease, and Huntington’s Disease that are caused by the misfolding, aggregation, and toxicity of certain proteins.
This review discusses how C. elegans models of protein misfolding have contributed to our current understanding
of the proteostasis network, its buffering capacity, and its regulation.
Reviewers: This article was reviewed by Luigi Bubacco, Patrick Lewis and Xavier Roucou.Background
Inherited mutations or polymorphisms, error-prone
protein synthesis, environmental stress, and damage
accumulated during aging all conspire against cells and or-
ganisms by challenging their ability to maintain a healthy
proteome. Because cells are under a constantly fluctuating
state of proteotoxic stress, there are built-in safeguards −
mechanisms by which cells and organisms regulate the
rates of protein synthesis, folding, and clearance to
minimize protein misfolding and aggregation. The result-
ing equilibrium in protein metabolism is referred to as
protein homeostasis, or simply as “proteostasis” [1].
The study of how proteostasis is regulated has in-
volved molecular chaperone-centric, aging-centric, or
disease-centric approaches. C. elegans has proven to be an
exceedingly useful genetic model system for all three
general approaches. Namely, it has been used to study
molecular chaperone function, identify genetic pathwaysCorrespondence: eakikis@sewanee.edu
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aggregation-prone disease-associated proteins as a means
to perturb the protein folding environment and investigate
how the C. elegans proteostasis machinery responds [2, 3].
This review focuses on transgenic C. elegans in which
one of eight different aggregation-prone disease-associated
proteins (Htt, ataxin-3, SOD1, Aβ, tau, α-syn, TDP-43 and
a polyQ peptide fused to YFP) has been expressed in one
of three tissues (body wall muscle, neurons, or intestines).
These models (and related models of endogenous
misfolded protein) have significantly advanced our under-
standing of the following:
1. The proteostasis network and how certain cellular
factors respond to changes or fluctuations in the
protein folding environment.
2. The ways in which genetic background impacts the
protein folding environment and consequently the
aggregation and toxicity of disease-associated
proteins.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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regulate proteostasis during aging, perhaps
explaining why neurodegenerative disease symptoms
do not appear until middle age or later.
4. The role of neurons in controlling proteostasis in a
cell non-autonomous manner.
5. The identification of small molecule regulators of
proteostasis as potential therapeutic interventions
for diseases of protein misfolding (Fig. 1).
Neurodegenerative disease-associated proteins expressed
in C. elegans
Many neurodegenerative diseases are characterized by
protein misfolding and aggregation, which seem to be trig-
gers for or causes of neurodegeneration in patients. For
example, Alzheimer’s Disease (AD), Parkinson’s Disease
(PD), familial amyotrophic lateral sclerosis (FALS)/Lou
Gehrig's disease, Huntington’s Disease (HD) and related
polyglutamine (polyQ) diseases, such as Spinal and Bulbar
Muscular Atrophy (SBMA)/Kennedy’s Disease, Dentator-
ubral - pallidoluysian atrophy (DRPLA), and spinocerebel-
lar ataxias (SCA) are all characterized by the misfolding
and aggregation of proteins and are therefore considered
to be conformational disorders [4]. To model protein
misfolding in C. elegans, aggregation-prone human pro-
teins associated with many of these diseases have been
expressed in a variety of C. elegans tissues (Fig. 2).
C. elegans, with its powerful genetics, relatively simple
body plan, and short life cycle is well-suited to modelFig. 1 Using C. elegans models of protein folding to study the regulation o
sensors, disease-associated aggregation-prone proteins and metastable end
proteostasis network, reveal how natural variation and genetic background
declines during aging, and identify small molecule regulators of proteostas
sensors to the research areas in which each was employed as a toolmany aspects of protein misfolding, aggregation, and
toxicity, to identify genetic modifiers, and to test pu-
tative therapeutics. Additionally, many neurodegenera-
tive disease-associated proteins are expressed widely
but nonetheless display cell type-specific differences
with respect to toxicity. C. elegans studies in which
human disease-associated proteins are expressed in
different C. elegans tissues allow such differences to
be examined genetically.
Each disease-associated protein expressed in C. elegans
has its own unique aggregation properties. Even the
most closely related proteins, such as those containing a
polyQ tract, differ with respect to aggregation propensity
and interaction with the protein folding environment.
For example, polyQ is much more aggregation-prone on
its own than when it is embedded within the context of
a disease-associated protein [5, 6]. Furthermore, short
fragments of the HD-associated htt protein are less sus-
ceptible to protein turnover than longer fragments [7],
and the immediate N-terminus of htt has been shown to
interact with certain molecular chaperones [8, 9].
Models of polyQ protein aggregation and toxicity
PolyQ disorders (HD, MJD, SBMA, DRPLA, and five
different spinocerebellar ataxias) are a unique subset
of neurodegenerative disorders in that the genetic deter-
minant for each is an expansion of a polyQ-encoding
CAG trinucleotide repeat. The polyQ expansion leads to
the toxic gain-of-function of a misfolded and aggregation-f proteostasis. This review discusses how two different types of folding
ogenous proteins (shown in blue), have been used to uncover the
modulate the protein folding environment, reveal how proteostasis
is (shown in red). Black lines connect the two categories of folding
Fig. 2 Disease-Associated Proteins Expressed in C. elegans. a Schematic representation of C. elegans showing body wall muscle cells (red),
neuronal cells (blue), and intestinal cells (green). Disease associated proteins are indicated and the arrows point to the tissues in which they have
been expressed. b Each box represents a tissue including body wall muscle cells (red), neuronal cells (blue), and intestinal cells (green). The
disease-associated proteins that have been expressed in each tissue are indicated in the corresponding box
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are entirely unrelated to each other, outside of the polyQ
tract, both in primary sequence and in function. However,
the length of the polyQ tract is inversely proportional both
to the age of onset of disease symptoms, the severity of
symptoms, and in many cases the lifespan of affected pa-
tients [10–12].
The first invertebrate model for polyQ protein misfold-
ing, aggregation, and toxicity to take advantage of the
power of C. elegans genetics was generated in 1999 in the
laboratory of Anne Hart [13]. In that model, a polyQ-
containing N-terminal fragment of the human htt gene
was expressed in C. elegans sensory ASH neurons. Animals
were generated that had either normal (2 or 23) polyQ
repeat lengths or disease-associated polyQ (95 or 150)
expansions resulting in ASH neuron degeneration [13].
To further study the phenomenon of polyQ length-
dependent aggregation and toxicity, and to consider the
hypothesis that the polyQ tract in and of itself is suffi-
cient to cause disease in a manner independent of its
normal protein context, the laboratory of Richard Mori-
moto developed generic polyQ models in which the
polyQ tract alone was fused to Yellow Fluorescent Pro-
tein (YFP) for visualization in body wall muscle cells [6]
or neurons [14]. These studies revealed that polyQ alonefused to YFP (polyQ-YFP) forms aggregates in C. elegans
in a polyQ length-dependent manner that mimics that
which is observed in HD patients. Furthermore, expres-
sion of polyQ-YFP, either in body wall muscle cells [6]
or neurons [14], led to motility defects, which served as
an indication of toxicity. PolyQ-YFP was also expressed
in C. elegans intestinal cells and used as a sensor for
proteotoxic stress that occurs in response to infection
[15]. Taken together, these models demonstrated that
expanded polyQ tracts are toxic to many different C.
elegans tissues.
My laboratory focuses on specific polyQ-containing
proteins and asks how the sequences flanking the polyQ
tract in disease-associated proteins influence aggregation
and toxicity. To this end, we have expressed a polyQ-
containing C-terminal fragment of the MJD-associated
Ataxin-3 protein in body wall muscle cells [5]. The same
Ataxin-3 fragment was also expressed in neurons [16].
Likewise, we expressed a polyQ-containing N-terminal
fragment of the human htt protein in C. elegans body
wall muscle cells. In every case, the proteins with ex-
panded polyQ tracts aggregate in and are toxic to the
tissues in which they are expressed [5, 6, 14]. However,
increased aggregation during aging has been observed
for some models [6, 14] but not others [5].
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Alzheimer’s Disease (AD) is the leading cause of demen-
tia worldwide, affecting ~30 % of all individuals over
85 years of age. Its genetics are less straightforward than
that of polyQ disorders, as it is polygenic and character-
ized by the misfolding and aggregation of several differ-
ent proteins, including the amyloid β (Aβ) peptide and
tau. The Aβ peptide is derived from the amyloid precur-
sor protein (APP) and forms amyloid plaques in the
brains of AD patients. APP is a single-pass transmem-
brane protein of which a large domain sits at the extra-
cellular surface. The function of this protein is not well
understood, but it may be involved in regulating gene
expression in a manner similar to Notch [17]. When
APP is cleaved sequentially by the proteases α-secretase
and γ-secretase at the cell surface, the AD-associated
Aβ1–42 peptide is not produced. However, certain mu-
tant forms of APP are internalized into vesicles contain-
ing β-secretase (BACE1) and γ-secretase that cleave it to
produce the disease associated Aβ1–42 peptide, which is
then secreted and forms extracellular amyloid plaques in
a concentration-dependent manner [18, 19].
Consistent with Aβ toxicity being concentration-
dependent, Down’s syndrome is characterized by APP
overexpression due to trisomy 21 leading to an extra
copy of the APP gene. This APP overexpression leads in
turn to Aβ deposition in the brains of individuals as
young as 30 years of age [20–22]. Likewise, the trinucle-
otide repeat disorder known as fragile X syndrome leads
to an upregulation of APP and Aβ production, leading
to impaired neurodevelopment [23]. Finally, a subset of
the otherwise healthy population carries the APOE4 allele
encoding apolipoprotein isoform 4 that significantly in-
creases the risk of developing AD and is associated with
increased Aβ deposition.
Various forms of the disease-associated Aβ peptide
have been expressed in C. elegans body wall muscle cells
and neurons to model aggregation and toxicity. The first
of these studies involved either the heat-inducible ex-
pression of the N-terminally truncated Aβ3–42 peptide in
C. elegans body wall muscle cells [24] or the expression
of that same truncated peptide in neurons [25]. Recently,
a full length Aβ1–42 peptide was expressed in C. elegans
body wall muscle cells and shown to be highly toxic, but
only to animals grown at elevated temperatures [26]. This
suggests that the mechanisms that regulate proteostasis
may be able to handle one stress, the Aβ1–42 peptide, or
heat shock, but not both. This is consistent with the
hypothesis that the proteostasis machinery is easily over-
whelmed when the misfolded protein load reaches a
certain threshold, as elevated temperature may trigger the
misfolding of some endogenous proteins. Alternatively, the
Aβ1–42 peptide may adopt an alternative conformation that
is more toxic than that achieved at lower temperatures.Tau, a-syn, SOD1, and TDP-43
Neurofibrillary tangles comprised of a hyperphosphory-
lated form of the microtubule-associated protein tau, are
characteristic not only of AD but also of other tauopa-
thies including an autosomal dominant form of fronto-
temporal lobar degeneration (FTLD), named FTDL-17
after the affected chromosome. Many mutations in the
gene encoding tau on chromosome 17 have been identi-
fied and shown to be the underlying genetic determinant
of familial FTDL-17 [27, 28]. While there may be a par-
tial loss of function phenotype caused by a failure of mu-
tant tau to interact with microtubules, FTDL-17 appears
to be inherited as a dominant disorder likely caused by
toxic gain-of-function associated with mutant tau [29].
This toxic gain-of-function hypothesis is supported by
the fact that overproduction of tau also leads to FTDL-
17. In short, mutant tau is thought to misfold, become
hyperphosphorylated, and aggregate in the human brain,
leading to characteristic and apparently toxic neurofibril-
lary tangles [29]. To model tau aggregation and toxicity,
the human tau protein was expressed in C. elegans neu-
rons and shown to cause neurodegeneration and disrupt
neurotransmission [30].
Not all cases of FTDL are familial. In fact, the most
common form of FTDL is a heterogenic sporadic dis-
order known as FTDL-U. Like familial forms of ALS,
FTDL-U is characterized by the presence of ubiquiti-
nated aggregates of misfolded proteins. Unlike FTDL-17,
the FTDL-U aggregates do not contain any tau. Instead,
they have been shown to contain the widely expressed
protein known as TDP-43 [31]. TDP-43 contains two
RNA recognition motifs and is likely involved in splicing
[32]. Interestingly, ubiquitinated TDP-43 aggregates have
also been identified in patients with sporadic forms of
ALS [31], indicating that these two neurodegenerative
diseases have related neuropathologies. To model TDP-43
aggregation and toxicity, has been expressed in C. elegans
neurons and shown to be neurotoxic [33]. Familial forms
of ALS are caused by mutations in Superoxide Dismutase
1 (SOD1) which was also expressed in C. elegans body
wall muscle cells and shown to aggregate and cause dele-
terious effects on muscle cell function [34].
Another misfolded and aggregation-prone protein asso-
ciated with a subset of neurodegenerative disorders is the
synaptic protein α-synuclein. α-synuclein aggregates and
forms proteinaceous deposits known as Lewy bodies in the
brains of PD patients. PD is a progressive neurodegenera-
tive disorder characterized by tremors, rigidity, and loss of
dopaminergic neurons in the substantia nigra. The human
α-synuclein gene was the first PD gene to be identified
[35]. At least three different point mutations in α-synuclein
have been described as genetic determinants for rare dom-
inantly inherited familial forms of PD [35–37]. α-synuclein
has been expressed in both neurons [38] and body wall
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dysfunction and motor loss [38, 39].
α-synuclein has been shown to move from cell to cell
in a number of studies including some in which un-
affected neurons were grafted to PD-affected brains. The
grafted neurons picked up α-synuclein, which in turn
seeded aggregation [40–42]. This is reminiscent of the
behavior of prion proteins.
Prions
Prions are infectious proteins that have the ability to adopt
self-propagating conformations. The prion protein (PrPSc)
is responsible for transmissible spongiform encephalop-
athies [43–45]. Like many of the disease-associated pro-
teins described above, PrPSc forms inclusions of misfolded
protein. Interestingly, PrPSc seeds the misfolding and ag-
gregation of the initially natively folded PrPC [46]. Recent
evidence suggests that PrPSc may not be unique in its in-
fectious nature and that other misfolded and aggregation-
prone protein may have prion-like properties [47, 48].
Some of the first evidence that disease-associated aggre-
gates may propagate in a prion-like manner came from the
studies with Lewy bodies described above. In addition, in-
jection of Aβ into mice overexpressing APP triggered
plaque formation [49]. Finally, HD-associated htt aggre-
gates were shown to be taken up by cultured cells and,
once inside, to seed the aggregation of previously soluble
htt [50]. Yeast also have endogenous prions, including a re-
gion of the Sup35 protein [45]. The prion domain of Sup35
was expressed in C. elegans body wall muscle cells where it
too displays aggregation and toxicity [51]. The mouse prion
protein (MoPrP) was also expressed in C. elegans body wall
muscle cells yielding a range of phenotypes from com-
pletely normal to completely paralyzed [52].
Endogenous Metastable Proteins as Folding Sensors
While disease-associated proteins have been used as tools
to probe the protein folding environment and elucidate the
cellular mechanisms underlying proteostasis, endogenous
metastable proteins have also proven to be powerful sen-
sors of the protein folding environment. Specifically,
temperature sensitive mutant variants of certain C. elegans
proteins including paramyosin, myosin, dynamin, ras and
perlecan have been used as endogeneous folding sensors.
While the temperature sensitive proteins normally fold into
their native conformation at permissive temperatures, their
folding was shown to be impaired in the presence of ex-
panded polyQ [34, 53] or during other conditions of known
or presumptive proteotoxic stress such as aging [54].
The proteostasis network
Several of these models of protein misfolding in C. elegans
have been used to elucidate the proteostasis network. The
“proteostasis network” refers to the complement of cellularproteins that together are responsible for regulating pro-
teostasis and buffering the folding capacity of cells. Mo-
lecular chaperones are obvious candidates for membership
in the proteostasis network, as they are able to assist in the
folding, disaggregation, and clearance of nascent polypep-
tide chains and damaged proteins. The protein folding
models and sensors described herein are indispensible
tools for the identification of factors that comprise the pro-
teostasis network. Because of the availability and ease of
use of genome-wide RNAi libraries for gene knockdown in
C. elegans, many of the first efforts to elucidate the proteins
of the proteostasis network involved genome-wide RNAi
screens. One study involved a screen for genes that when
knocked down resulted in an increase in the aggregation of
expanded polyQ-YFP in body wall muscle cells [55]. That
study uncovered components of the chaperonin-like CCT
molecular chaperone complex as well as genes and pro-
teins that function at different points in the maturation of
a protein – as early as transcription and as late as protein
degradation. A complementary screen for genes that re-
sulted in a decrease in both polyQ and mutant SOD1 ag-
gregation when knocked down has expanded our list of
proteostasis network components to include additional
proteins involved in metabolism and RNA processing [56].
Another large-scale genome-wide screen for proteosta-
sis regulators took advantage of a gene expression reporter
for the heat shock response (HSR), in which GFP expres-
sion was under the control of a heat-inducible promoter.
This analysis uncovered genes whose downregulation trig-
gered an HSR in the absence of heat stress and genes
whose downregulation suppressed an HSR under condi-
tions when it would normally occur [57]. This study led to
the identification of some of the same factors responsible
for suppressing polyQ-YFP aggregation, including the
CCT chaperonin complex and proteasomal subunits [55,
57], suggesting that these macromolecular machines play
particularly important roles in regulating proteostasis.
Taking the slightly different approach of using the
temperature sensitive mutants as folding sensors, the
Ben-Zvi laboratory identified molecular chaperones
that are required for muscle homeostasis in C. elegans
[58]. Specifically, they uncovered Hsp90 and its co-
chaperones Sti-1, Aha1, and Cep23 [58].
Molecular chaperones, consistently being identified in
screens for members of the proteostasis network, may
comprise the network’s core. Therefore, a targeted study
was performed to identify the full complement of molecu-
lar chaperones that enhance proteostasis under conditions
in which the misfolded protein load was altered by the ex-
pression of neurodegenerative disease-associated proteins.
All 332 molecular chaperones of C. elegans were knocked
down by RNAi in animals expressing either Aβ3–42 or ex-
panded polyQ-YFP in body wall muscle cells. Yet again,
the CCT chaperonin complex was identified along with
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two DnaJ chaperones (dnj-8 and dnj-12) that likely act as
Hsp70 co-chaperones [59].
Interestingly, another DnaJ protein, DNJ-27, was shown
to act as a proteostasis regulator based on the fact that its
knockdown by RNAi triggered increased aggregation and
toxicity of Aβ3–42, α-synuclein, and polyQ-YFP [60]. This
finding is especially intriguing because DNJ-27 is an ER-
resident protein. The Aβ precursor protein, APP, is nor-
mally a membrane protein and thus associates with the ER.
Likewise, α-synuclein disrupts vesicular trafficking [61],
likely feeding back to cause imbalances in ER homeostasis.
However, there is no evidence or expectation for polyQ,
which is a cytosolic protein, to disrupt the ER. Thus, these
data suggest that DNJ-27 levels in the ER affect proteosta-
sis in the cytosol, possibly through signaling or crosstalk.
Other targeted studies have explored whether certain
genes or pathways are involved in regulating proteosta-
sis. Namely, the O-GlcNac nutrient-dependent post-
translational modification, which has been implicated in
AD [62, 63], was tested for a role in protein aggregation
and toxicity. Specifically, the authors examined the effect
of O-GlcNac modification in the aggregation and tox-
icity of pan neuronal tau, Htt-Q150 in ASH neurons,
poly-YFP, and Aβ3–42 expressed in C. elegans body wall
muscle cells [64]. These studies revealed that O-GlcNac
cycling is neuroprotective in C. elegans [65] and likely
acts by altering rates of protein turnover [66] and by
modulating insulin-like signaling [67], an important
pathway for C. elegans aging.
Finally, more members of the proteostasis network
were identified via proteomics approaches. In one such
study, proteins that physically interact with polyQ-YFP
were isolated by immuno-precipitation and identified by
mass-spectroscopy [68]. Glutamine and asparagine-rich
(pqn) proteins were found to have an especially high af-
finity for binding to polyQ-YFP aggregates. However,
one non-pqn protein, CRAM-1, seems to be a primitive
molecular chaperone that binds less efficiently than the
pqn proteins, but plays a larger role than they in actually
blocking aggregate clearance [68]. Together, these find-
ings greatly expand our understanding of the vast scope
of proteins and pathways that together regulate proteos-
tasis. In short, the proteostasis network seems to operate
at all the points along the pathway for protein synthesis
and maturation. Specifically, it includes transcriptional reg-
ulators, splicing factors, the protein synthesis machinery
including ribosomal subunits, molecular chaperones, and
factors involved in protein turnover (Fig. 3).
Genetic background affects the protein folding
environment
The important role that genetic background plays in
modulating the folding of the HD-associated htt proteinwas evident in some of the first studies of HD and its
causative genetic anomaly. An inverse correlation be-
tween polyQ tract length and age-of-disease-onset was
reported at the time that the HD gene was first identi-
fied [69]. However, this correlation is not exact, as a cer-
tain polyQ length does not perfectly predict the age at
which disease symptoms will appear [12]. A more com-
prehensive study of the role that genetic background
plays in modulating age of HD onset was performed
using an extensive cohort of HD patients in a remote
part of Venezuela [70]. The data showing the large range
of age-of-onset, even for the same polyQ lengths within
this Venezuelan cohort, is reproduced here (Fig. 4a).
Studies involving some of the C. elegans models of
protein folding have nicely recapitulated the findings
that genetic background influences the protein folding
environment and thereby affects the aggregation and
toxicity of disease-associated proteins. The first evidence
of this in C. elegans came from a study using the
temperature sensitive mutants to ever so slightly modu-
late the folding environment in the background of
polyQ-YFP expression. A metastable temperature sensi-
tive protein in the background of polyQ-YFP caused
polyQ to aggregate more readily than it does in the wild
type background [53]. However, the temperature sensi-
tive proteins and polyQ-YFP did not physically interact,
meaning that they did not seed the aggregation of each
other. Instead, the proteostasis network likely suffers
from limited resources, meaning that under conditions
that lead to an increased load of misfolded proteins, the
network becomes overwhelmed and unable to prevent
protein misfolding and aggregation. Furthermore, the ex-
pression of ALS-associated mutants of SOD1 in the
background of temperature sensitive mutations also re-
sulted in reciprocal misfolding of the temperature sensi-
tive proteins and mutant SOD1 [34, 53]. Together, the
findings led to the hypothesis that naturally occurring
destabilizing polymorphisms encoded in one’s genetic
background may serve to overwhelm the proteostasis
machinery, leading to the onset of disease symptoms [2].
To test this, polyQ-YFP expressed in C. elegans body
wall muscle cells [6] was introgressed into four different
wild isolates and used to generate a series of recombin-
ant inbred (RI) lines [71]. The R1350 wild isolate caused
the highest amount of polyQ aggregation and the least
amount of toxicity [71], fortuitously supporting the hy-
pothesis that the large visible aggregates are cytoprotec-
tive rather than toxic [72]. When RI lines were
generated by crossing animals carrying the polyQ-YFP
transgene in the N2 laboratory background to the
DR1350 wild isolate and then inbreeding, a wide range
of aggregation propensity was observed, demonstrating
that genetic background is a potent modifier of polyQ
aggregation and toxicity. This also provides support for
Fig. 3 The Proteostasis Network. The pathway for protein synthesis and maturation is shown with specific cellular processes indicated with blue
arrows and pathway intermediates indicated in circles. The functional categories of proteins that have been identified as members of the proteostasis
network are shown in boxes, with→ representing positive regulation and —| representing negative regulation. The thick arrow for on-pathway folding
represents the fact that for most proteins under normal non-stress conditions, on-pathway folding predominates over off-pathway folding
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overwhelmed when the number of destabilizing poly-
morphisms is too high, especially when combined with
an aggregation-prone disease-associated protein.
Thus, the ability to achieve proteostasis declines as the
load of misfolded protein increases (Fig. 4b). The load of
misfolded protein is higher in some genetic backgrounds
than others due to the presence of destabilizing poly-
morphisms. Likewise, the presence of disease-associated
aggregation-prone proteins, and damage accumulated
over an individual’s lifetime, likely all work together withthe genetic background to challenge the proteostasis ma-
chinery, leading to an eventual collapse of proteostasis.
Age-related decline in proteostasis
Damage to DNA and proteins that occurs over the
course of aging could be the proverbial final straw that
tips the balance of proteostasis away from a healthy
proteome and into the realm of disease (Fig. 4b). This is
especially true when disease-associated proteins or other
metastable proteins are already present. The first evi-
dence that an aging proteome significantly impairs the
Fig. 4 Genetic Background Affects the Protein Folding Environment. a Age of Huntington’s Disease onset as a function of polyQ repeat length
(adapted from Wexler, et. al., (2004) Proc. Natl., Acad. Sci.). b Schematic representation of the decline in proteostasis buffering capacity as the
misfolded protein load increases. Three sources of misfolded protein are considered, including destabilizing polymorphisms in the genetic background
(red), disease-associate proteins (brown), and sporadic mutation to DNA or accumulated damage during aging (blue). Symptoms associated with
neurodegenerative disease or aging are more likely to be observed when the misfolded protein load is sufficiently high (shaded in pink) as compared
to normal (green) or intermediate levels (yellow) of misfolding
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temperature sensitive folding reporters during an aging
time course. These proteins were shown to misfold at
a permissive temperature early in the aging process, in-
dicating that the buffering capacity of the proteostasis
network was likely overwhelmed by the combination of
a metastable protein and damage accumulated during
aging [54].
Even under wild type conditions without the presence
of folding sensors or disease-associated proteins in the
genetic background, large-scale protein misfolding has
been shown to be a hallmark of C. elegans aging.Endogenous proteins were separated based on solubility
and a measureable increase in the insoluble fraction in
older animals was observed [73]. Overexpression of some
of the proteins that undergo an age-dependent decline in
solubility triggered enhanced aggregation of polyQ-YFP,
providing further evidence that an age-dependent decline
in proteostasis triggers late age-of-onset of neurodegener-
ative diseases [73]. Importantly, the mere fact that aggre-
gation of endogenous proteins increases during aging
indicates that as damage accumulates to a great enough
extent that the proteostasis network becomes over-
whelmed even without the additional assault of a disease-
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a cause of normal aging and not just the trigger for the ap-
pearance of neurodegenerative disease symptoms.
Large-scale proteomics studies provided yet more
evidence that proteostasis decline underpins aging. In
one study, 5,000 proteins were profiled during aging,
and one third were found to change in abundance,
causing loss of normal stoichiometry for important
molecular complexes including the ribosome [74].
The upregulated proteins formed insoluble aggregates in
an age-dependent manner [74]. In two other studies, the
protective heat shock response, a core component of the
proteostasis network, was shown to decline measurably
during aging [54, 75].
Having shown that the capacity of the proteostasis net-
work to buffer protein misfolding declines precipitously
at the transition to C. elegans adulthood [54], the
Ben-Zvi laboratory asked whether there are certain
physiological processes that occur specifically during this
developmental transition that result in an increase in pro-
teotoxic stress dramatic enough to overwhelm the pro-
teostasis machinery. To address this, they considered the
possibility that the onset of reproduction may be the trig-
ger for proteostasis decline [76]. They found that germ
line stem cell arrest rescued proteostasis in a manner
dependent on a number of signaling pathways including
the heat shock response and the insulin-like signaling
pathway [76]. This led to the conclusion that germ line
stem cell proliferation likely sends a signal to the somatic
cells that suppresses the activity of stress responses
thereby leading to an overall decline in somatic proteosta-
sis [76]. This finding is especially noteworthy because it
indicates that the buffering capacity of the proteostasis
network is so limited that even normal developmental
programs cause changes that are too much for the pro-
teostasis machinery to handle.
Neuronal regulation of protein misfolding and the heat
shock response
The heat shock response (HSR) is a transcriptional re-
sponse to proteotoxic stress that results in the upregula-
tion of the expression of genes that encode molecular
chaperones known as heat shock proteins (Hsps). In
eukaryotes, the HSR is controlled by the heat shock
transcription factor (HSF1), which is activated under
environmental conditions that are damaging to proteins,
such as a sudden increase in temperature of as little as a
few degrees. Under normal conditions when proteins do
not experience substantial thermal stress and are thereby
in their native conformations, HSF1 is held in an inactive
state, outside of the nucleus, via interaction with molecu-
lar chaperones. Under conditions of thermal stress, cellu-
lar proteins may begin to denature. When this happens,
the molecular chaperones release and thereby de-repressHSF1 and bind instead to their preferred partner –
misfolded protein. Once de-repressed, HSF1 enters
the nucleus, binds as a trimer to the DNA consensus
sequence referred to as the heat shock element (HSE)
and activates the transcription of Hsps. This results
in a negative feedback loop wherein the newly synthe-
sized Hsps not only aid in the folding of damaged
cellular protein but also re-repress HSF1 [77–80].
Until relatively recently, most of what we knew about
the HSR was based on work utilizing individual cells in
tissue culture. To understand how C. elegans regulate
the HSR on an organismal rather than cellular level,
Prahlad et al. (2008) examined the HSR in C. elegans
lacking functional thermosensory AFD neurons. They
found that animals whose AFD neurons were genetically
ablated with a mutation in the gene gcy-8 were unable to
launch an HSR [81]. Their data provided some of the
first evidence that the AFD thermosensory neurons must
serve to determine when it is appropriate to launch an
HSR and to alert the rest of the animal. The Prahlad la-
boratory further showed that the organismal HSR in C.
elegans is dependent on the release of serotonin [82].
Serotonin release not only triggered the HSR, but also
suppressed the aggregation of the exogenous polyQ-YFP
protein in body wall muscle cells [82]. This is consistent
with the previous findings that the C. elegans nervous
system normally blocks the ability of non-neuronal tis-
sues, including the body wall muscle cells, and intestinal
cells to cell autonomously suppress polyQ-YFP or mutant
SOD1 aggregation and toxicity [83] and that blocking
serotonin reuptake reduces the aggregation of ataxin-3 in
C. elegans neurons [84].
Taken together, these data suggest that thermosensory
neurons act as control centers that induce the HSR
under conditions of thermal stress and that block the
ability of non-neuronal cells to launch an HSR under
normal conditions. This means that cell autonomous
heat shock responses cannot occur when individual
cells or tissues experience an increase in the aggrega-
tion of a disease-associated protein. However, when
thermosensory neuron function is ablated, C. elegans
is unable to launch an organismal HSR, but is able to
induce a cell-autonomous response to the presence of
disease-associated proteins, thereby reducing protein
aggregation (Fig. 5a).
Chemosensory neurons have also been implicated in
regulating both the organismal HSR and the toxicity of
the Aβ peptide. Specifically, a G-protein coupled recep-
tor (GPCR) that is expressed in chemosensory neurons
is required for C. elegans to launch an organismal HSR
[85]. Additionally, knockdown of this GPCR dubbed
gtr-1 reduced the toxicity of the Aβ peptide [85], reminis-
cent of the effect of thermosensory neuron disruption on
mutant SOD1 or polyQ aggregation [83].
Fig. 5 Neuronal Regulation of Protein Misfolding and the Heat Shock Response. a Top: Sensory neurons induce the organismal HSR under
conditions of acute thermal stress and block the upregulation of Hsps in non-neuronal tissues under conditions of chronic misfolding but normal
temperature. Bottom: Genetic ablation of sensory neurons results in an inability to launch an organismal HSR, but de-repression of Hsp expression
results in their upregulation in non-neuronal tissues and concomitant suppression of the aggregation of disease-associated proteins. b Cholinergic
signaling at the neuromuscular junction (NMJ). Red dots represent acetylcholine and the acetylcholine receptor (AchR) is indicated. Left: normal
conditions; middle: conditions of moderate increase in acetylcholine signaling to upregulation of the AchR; right: extreme increase in acetylcholine
signaling due to lack of the inhibitory neurotransmitter GABA. Downstream effects on aggregation and toxicity of disease-associated proteins
are indicated. c Schematic graphical representation of the effects of cholinergic signaling on the aggregation of disease associated proteins.
The green block represents the narrow window during which acetylcholine signaling is neither too high nor too low to suppress aggregation
via the induction of a heat shock response in muscle cells
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leads to the upregulation of molecular chaperones. An-
other important pathway is the insulin/IGF signaling
(IIS) cascade that suppresses the activity of the forkhead
transcription factor known as DAF-16 in C. elegans [86].DAF-16 activity promotes longevity by inducing the ex-
pression of molecular chaperones [87]. A chemosensory
protein, NHL-1, acts as a DAF-16 co-factor and is required
for stress-resistance in a DAF-16-dependent, but not
HSF-1-dependent, manner. Importantly, its knockdown in
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of the Aβ peptide [88]. Thermosensory neurons regulate
the HSR via serotonin release [82], and it is likely that che-
mosensory neurons work in a similar manner [89].
Cholinergic signaling at the neuromuscular junction
(NMJ) also modulates the aggregation and toxicity of
disease-associated aggregation-prone proteins expressed
in C. elegans body wall muscle cells. In one study, cho-
linergic signaling was significantly upregulated by the
complete abrogation of the inhibitory neurotransmitter
GABA [90]. In another study cholinergic signaling
was only moderately increased due to a mutation that
resulted in the upregulation of the acetylcholine receptor
at the NMJ [91]. A moderate increase in cholinergic
signaling suppressed the aggregation/toxicity of the
disease-associated proteins polyQ-YFP and mutant
SOD1, and suppressed the misfolding of the temperature-
sensitive folding sensors [91] (Fig. 5b). In contrast, ex-
treme upregulation of cholinergic signaling increased the
aggregation of polyQ-YFP [90], indicating that the ability
of C. elegans to regulate proteostasis is highly sensitive to
relatively slight changes in cholinergic signaling at the
NJM (Fig. 5b). Thus, there seems to be a narrow window
of cholinergic signaling levels that is able to mitigate the
deleterious effects of disease-associated proteins [91]
(Fig. 5c). Cholinergic signaling at the NMJ and signaling
from the serotonergic sensory neurons likely work to-
gether to balance proteostasis in non-neuronal tissues
in response to thermal stress and changes to the load
of misfolded proteins due to aging and disease.
Small molecule regulators of proteostasis
We have learned a great deal using C. elegans as a model
system to study the cellular and molecular biology
underlying conformational diseases and the maintenance
of proteostasis. One important finding is that while the
proteostasis network is controlled in many ways, including
by neurons, its capacity to buffer against protein misfold-
ing is limited. This means that subtle changes in the fold-
ing environment that occur during aging can significantly
impact the health of the proteome. The ability to pharma-
cologically boost the network’s buffering capacity has the
potential to serve aging members of our society, especially
those at risk for neurodegenerative disease. Several screens
for small molecule regulators of proteostasis have led to
the identification of candidate molecules.
While upregulation of molecular chaperones seems to
be an obvious strategy for mitigating the toxic effects of
misfolded aggregation-prone disease-associated proteins
by helping them to attain their native conformations,
there is some evidence that inhibiting molecular chaper-
ones may actually switch the balance from folding to
degradation, thereby promoting the clearance of toxic
proteins [92]. This suggests that any sort of treatmentthat tips this balance, including, perhaps, molecular
chaperone downregulation and direct activation of clear-
ance pathways, may likewise be effective in ameliorating
the toxic effects of misfolded aggregation-prone protein.
In addition to directly targeting molecular chaperones
for pharmacological activation or inhibition, the heat
shock response has been targeted to increase molecular
chaperone levels in the absence of thermal stress. Calamini
et al. (2012) screened a library of 900,000 small molecules
for their ability to induce an HSR and reduce the aggrega-
tion of polyQ expanded human htt protein in cells in tissue
culture [93]. The small molecules identified were then
tested for their ability to suppress polyQ-YFP aggregation
in C. elegans body wall muscle as evidence of the mole-
cules working in the context of an organism. Three small
molecules were identified that met all of these criteria [93].
At face value, small molecules that disrupt proteostasis
by causing protein misfolding and damage may be ex-
pected to induce an HSR. However, stress-independent
activation of the HSR via the direct activation of HSF1
suppresses the aggregation/toxicity of disease-associated
proteins [94]. Specifically, when HSF1 was activated,
molecular chaperone levels rose sufficiently for a sup-
pression of polyQ-YFP aggregation in C. elegans body
wall muscle cells [94].
Because the transcription factor DAF-16 also controls
molecular chaperone expression, pharmacological activa-
tion of DAF-16 directly or indirectly via the suppression
of the IIS pathway may be a viable method to increase
the buffering capacity of the proteostasis network and
simultaneously to increase lifespan and reduce the ag-
gregation and toxicity of disease-associated proteins. To
identify such small molecules, the Cohen laboratory
screened a family of IIS inhibitors [95] and found one
that suppressed Aβ3–42 and polyQ-YFP aggregation and
toxicity in C. elegans body wall muscle cells [96]. Inter-
estingly, this inhibitor had no effect on longevity [96].
The laboratory of Stephen Pak performed two screens
for small molecules that suppressed the aggregation and
reduced the accumulation of the mutant form of α1-
antitrypsin (ATZ) that is the genetic determinant for the
disease α1-antitrypsin deficiency. In one study, they devel-
oped a high-content drug screen that revealed 33 such
small molecules [97]. In a follow-up screen, they performed
genome-wide RNAi to identify genes that when knocked
down either increased or decreased the accumulation of
the ATZ variant of α1-antitrypsin in C. elegans. They then
identified four FDA approved drugs that either enhanced
or suppressed the activity of the genetic modifiers and con-
sequently suppressed the accumulation and aggregation of
α1-antitrypsin ATZ mutant [98]. Together, these data sup-
port the therapeutic potential of small molecule proteosta-
sis regulators to suppress the toxicity of proteins associated
with conformational disease and aging.
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C. elegans models of protein misfolding have contributed
greatly to our current understanding of the proteostasis
network, its buffering capacity, and its regulation. Four-
teen different models of protein misfolding have been
described, including nine different neurodegenerative
disease-associated proteins, each expressed in up to
three possible tissue types. One of the most striking
findings to come from studies of these models is just
how limited cells and organisms are in their ability to
buffer protein misfolding. Neurons play an integral role
in regulating the organismal HSR and seem to contrib-
ute to the limited buffering capacity − at least when the
misfolded protein load increases in the absence of a trig-
gering environmental stress such as heat shock. Finding
ways to combat this inherent limitation in the buffering
capacity of the proteostasis network is crucial for the
treatment of patients suffering from protein folding disor-
ders. To this end, many small molecules have been identi-
fied for the purpose of pharmacologically enhancing the
ability of cells and organisms to handle the expression of
chronically misfolded disease-associated proteins. An im-
portant next step will be verifying the efficacy of these
molecules in mammalian models and human patients.
Such validation is especially important because the C.
elegans models described here are designed to recapitu-
late only very specific and limited aspects of disease, and
therefore cannot be treated as “disease models” per se.
Reviewers’ comments
I would like to thank all of the reviewers for taking the
time to carefully review this manuscript and provide
thoughtful comments and suggestions. I have carefully
considered all of the suggestions and have addressed each
of them in the text as described below.
Reviewer report 1
Luigi Bubacco, University of Padua
Reviewer comments
Recommendations
This is an interesting and comprehensive review centered
on the role that the model organism Caenorhabditis
elegans had in the investigation of protein misfolding
and in the unraveling of the processes that govern
proteostasis. This is a balanced and sound analysis of the
exiting literature, nicely written and I endorse it for publi-
cation. Few considerations are due to improve readability:
Line 68: The author may consider the possibility to pro-
vide to the readers the rationale to embark in the expres-
sion of the misfolding proteins in the different type of
tissues. It may be of interest to comment on the different
aggregation properties of the thirteen different paradigmsof protein misfolding described in the review and how
these properties impact on the proteostasis.
Author’s response: Thank you for your kind words and
helpful suggestions. I have addressed your comments
regarding “rationale” and “aggregation properties” in the
text with the addition of two paragraphs at the end of
the section titled “Neurodegenerative disease-associated
proteins.”
Reviewer report 2
Patrick Lewis, University of Reading
Reviewer comments
Summary
The manuscript from Kikis reviews the biology of
proteostasis relating to the experimental organism C.
elegans in health and disease. This is an important
area of research, as using C. elegans as a model system
allows whole organism investigations into proteostasis
that are difficult to carry out in other organisms. These
studies provide insights into the fundamental biology of
proteostasis, but also have important implications for a
number of human diseases. The review focuses on a range
of neurodegenerative diseases associated with protein ag-
gregation and accumulation for which worm models have
been generated, and is structured around noting what
models have been reported in for a range of disorders, be-
fore moving on to summarize how different aspects of the
proteostasis machinery have been investigated in relation
to these protein aggregates.
Recommendations
The background on the genetics and clinical presentation
of some of the proteins under consideration, for example
huntingtin, is excellent - however more detail is needed for
a number of the disorders presented. For example, when
discussing Alzheimer’s there is no reference to the mono-
genic forms of the disease. Mutations in APP, in particular,
are critical for understanding the role of abeta species in
AD - and it would also be useful to note the impact of gene
dosage of APP on the risk of dementia, both in terms of
gene duplications and chromosomal copy number varia-
tions in the case of trisomy 21. This is of particular import-
ance when considering the genetic evidence for protein
burden per se being a key issue in disorders of proteostasis.
Author’s response: The section on AD has been signifi-
cantly fleshed out in the revised manuscript. In particular,
APP mutations are now discussed along with the roles of α,
β, and Y secretases in APP processing and the formation of
disease-associated forms of Aβ. In addition, the involve-
ment of Aβ in Down’s Syndrome and fragile X syndrome
are addressed in the revised manuscript.
Likewise, the descriptions of tau, alpha synuclein,
tdp43 and sod1 are cursory. At a minimum there should
Kikis Biology Direct  (2016) 11:58 Page 13 of 16be a brief description of the genetic evidence linking
these proteins to disease - in the case of tau, mutations
in MAPT causing frontal lobar degeneration, in the case
of synuclein mutations and gene duplications/triplica-
tions (linking in to protein level burden) causing familial
Parkinson’s and dementia with lewy bodies.
Author’s response: The section on tau has been expanded
to include a discussion of MAPT mutants causing familial
forms of frontotemporal lobar degeneration as suggested. In
addition, the sections on TDP-43, alpha-synuclein, and
prions have been significantly expanded with respect to
mechanisms of action and disease-associated mutations.
The section of prion disorders is also very brief, and
misses several references including citations for models
examining PrP expression in c elegans.
Author’s response: Thank you for pointing this out. The
omission has been rectified with the C. elegans model for
mouse PrP now discussed in the text and added to Fig. 2.
It would also be of great interest to link prion behavior
across all of these proteins, an area of considerable re-
search at present.
Author’s response: The section on prions now includes
a discussion of recent data suggesting that all the
aggregation-prone disease-associated proteins discussed
in this review article may have prion-like properties.
There is a detailed description of reports relating to
different proteostasis systems in C. elegans, with an em-
phasis on protein chaperone responses. It would be use-
ful to provide a brief overview of the different systems
regulating protein production and degradation, perhaps
as a figure, which could be used to synthesize how these
systems work in concert.
Author’s comments: To address this suggestion, a new
figure (Fig. 3) was added that shows the pathway of pro-
tein synthesis and maturation and the functional cat-
egories of proteostasis network components that act at
each step.
One aspect of the manuscript that is in need of atten-
tion is highlighting the drawbacks of using C. elegans in
the context of human neurological disorders. It is notable
that many of the proteins that are examined in the re-
ported models do not have paralogs in the C. elegans gen-
ome, and while this provides an excellent opportunity to
dissect out certain aspects of the disease process by taking
a reductionist approach it does have drawbacks in terms
of extrapolating to the human disease situation.
Author’s comments: To address this suggestion, I now
conclude the paper with a sentence clarifying that the C.
elegans models described here are not meant to recapitu-
late all aspects of disease and thus “cannot be treated as
‘disease models’ per se.”
Reviewer report 3
Xavier Roucou, Université de SherbrookeReviewer comments
Summary
C. elegans models of protein misfolding have contributed
greatly to our current understanding of the proteostasis
network. This is a timely review in the field and it will
be very helpful for the scientific community in general.
The proteostasis community may also find this review
useful. The review is easy to read.
Recommendations
Major recommendations 1. An entire section (pages 9–12)
in the review reports many studies that used different strat-
egies to identify key members of the proteostasis network
(proteins and pathways that together regulate proteostasis).
The term "proteostasis network" appears several times in
the review. Yet, besides some chaperones that are men-
tioned in the text, this network remains mysterious. I sug-
gest to include a figure of the proteostasis network that
includes the key players. Obviously, the idea is not to write
a list of all players that were identified in C. elegans, but to
give an overview of what kind of regulators and pathways
are involved.
Author’s comments: Thank you for this suggestion. It is
similar to one also made by reviewer #2. As mentioned
above, I added a new figure (Fig. 3) to the revised manu-
script. It shows the pathway of protein synthesis and
maturation and the functional categories of proteostasis
network components that act at each step.
2. In the abstract, the author writes that "Additional
demand is placed on the proteostasis machinery during
aging by a gradual increase in misfolded protein that re-
sults from accumulated molecular damage triggered by
reactive oxygen species or other mutagens". Yet, this
issue is not discussed at all in the review. I recommend
to either elaborate on that topic in the review, or to re-
move this sentence from the abstract.
Author’s comments: The sentence to which the re-
viewer is referring originally stated “Additional demand
is placed on the proteostasis machinery during aging by
a gradual increase in damaged and misfolded protein
that results from accumulated molecular damage trig-
gered by reactive oxygen species or other mutagens.”
However, as the reviewer noted, I do not discuss reactive
oxygen species or mutagens. As those topics are outside
the scope of this article, I revised the sentence to say,
“Aging is associated with a gradual increase in damaged
and misfolded protein, which places additional stress on
the machinery of the proteostasis network.”
Minor recommendations
Page 11: alpha-synuclein is not a lysosomal protein. It
enters into the lysosome, where the protein is degraded.
But it is not a normal resident of the lysosome. Page 18:
give the name of the GPCR in the text.
Kikis Biology Direct  (2016) 11:58 Page 14 of 16Author’s comments: These errors and omissions have
been corrected in the revised manuscript.
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